Efficacy and safety of one-year treatment with slow-release nicotinic acid. Monitoring of drug concentration in serum.
The paper is aimed at evaluation of the efficacy and safety of one-year therapy with slow-release nicotinic acid (NA-SR). The study involved a group of 30 patients with hyperlipidemia of type II. The concentration of nicotinic acid in serum was determined using capillary electrophoresis. After the placebo period (2 months), NA-SR was applied at the dose of 1.5 g/d (2 months), and subsequently 2-3 g/d (10 months), on average 2.13 g/d. During the treatment with 2.0 g/d dose, the steady-state concentration of NA in serum was within a range of 2.7-4.9 microg/ml and with 3.0 g/d of 6.17-7.75 microg/ml. These doses of the drug were tolerated well and advantageously modified the serum lipids.
Chojnowska-Jezierska
J
J
Department of Clinical Pharmacology, Institute of Internal Medicine, MMA, The Biegañski Hospital, Lodz, Poland.
Adamska-Dyniewska
H
H
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D015415:Biomarkers / Q000097:blood; D003692:Delayed-Action Preparations; D005483:Flushing / Q000139:chemically induced; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009525:Niacin / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D013272:Stomach Diseases / Q000139:chemically induced; D013997:Time Factors; D016896:Treatment Outcome
D015415:Biomarkers; D003692:Delayed-Action Preparations; D009525:Niacin; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase